Endogenex Secures $50 Million in Series C Extension
Endogenex, a Minneapolis-based medical technology company focused on developing novel treatment solutions for Type 2 Diabetes, announced on March 25, 2026, that it has successfully closed a $50 million Series C extension funding round. The round was led by Arboretum Ventures, marking their first involvement with the company.
Focus on Type 2 Diabetes Treatment
Endogenex is actively working on a minimally invasive endoscopic procedure designed to address Type 2 Diabetes by targeting the duodenum, the first section of the small intestine. The company's innovative approach involves using non-thermal pulsed electric fields to treat inflamed tissue and promote healthy cell regeneration. This procedure aims to rectify the dysfunction in the gut that can exacerbate or even contribute to the onset of Type 2 Diabetes.
Use of Funds
The newly secured funding will be primarily allocated to complete the pivotal ReCET Clinical Study, which is essential for advancing Endogenex's regulatory pathway towards FDA approval. This study focuses on validating the effectiveness of their novel treatment in managing Type 2 Diabetes.
Leadership Perspective
Stacey Pugh, Chief Executive Officer of Endogenex, commented on the funding's impact, stating: "This financing puts us in a strong position to complete our pivotal study and take the ReCET System through FDA approval." Her statement underscores the company's commitment to advancing its treatment to a broader market, potentially offering a new solution for patients, healthcare providers, and systems worldwide.
Strategic Partnership and Future Steps
Endogenex's partnership with the Mayo Clinic highlights its collaborative approach in developing healthcare solutions. The company's strategy involves leveraging this relationship to further its research and development efforts, ensuring that the treatment not only reaches regulatory approval but also meets the needs of the global healthcare community.
With this significant funding round, Endogenex is poised to make substantial advancements in the treatment of Type 2 Diabetes, potentially improving the lives of millions affected by this chronic condition.